BioNTech Boosts CAR-T Manufacturing Prowess with Autolus Investment and mRNA Synergy
Synopsis: BioNTech strategically expands its CAR-T manufacturing and development capabilities through an investment in Autolus, a British CAR-T cell therapy firm, leveraging mRNA technology to potentially enhance CAR-T cell therapy for solid tumor treatments.